Core Viewpoint - Cannabis stocks have underperformed over the past five years, but recent positive regulatory changes in the U.S. may present long-term growth opportunities if the marijuana market expands significantly [1] Group 1: Canopy Growth - Canopy Growth is a leading player in the Canadian cannabis market with a diverse product portfolio, including dried cannabis flower, vapes, and edibles, and has a presence in multiple countries, including the U.S. [2] - Following President Trump's executive order to classify cannabis as a Schedule III substance, Canopy Growth may have expansion opportunities in the U.S. [3] - In Q3 2026, Canopy Growth reported net revenue of $54.62 million, a slight decrease of 0.3% year-over-year, but improved its net loss per share to $0.13 from $0.81 in the previous year [3] - If Canopy Growth can capitalize on U.S. opportunities and continue to reduce losses, it could yield strong returns [4] Group 2: Tilray Brands - Tilray Brands also has a comprehensive portfolio of cannabis products and operates in several countries, including the U.S., Germany, and Portugal, and has diversified into craft brewing and hemp-based products [5] - In Q2 of its 2026 fiscal year, Tilray reported net revenue of $217.5 million, a 3% year-over-year increase, while its net loss improved to $0.41 from $0.99 in the previous year [6] - Tilray is well-positioned to take advantage of emerging opportunities in the U.S. cannabis market, which could lead to significant share price increases if successful [6]

Financial Data and Key Metrics Changes - In Q1, net revenue increased by 49% to CAD 65.3 million from CAD 42.7 million in the same prior year period, primarily due to growth in the Canadian business, integration of Motif, and higher international sales [17] - Adjusted gross profit for the quarter increased by 67% to CAD 23.9 million compared to CAD 14.3 million in Q1 last year, supported by higher revenue and efficiency gains [17][18] - Adjusted EBITDA in Q1 was CAD 5.3 million, up 273% from CAD 1.4 million in the prior year period, driven by increased scale and higher international sales [20][21] - Net income for the quarter was CAD 20 million compared to a net loss of CAD 23 million in the same prior year period, reflecting a CAD 43 million year-over-year improvement [21][22] Business Line Data and Key Metrics Changes - In Q1, international sales reached CAD 5 million, up 55% from Q1 fiscal 2025, despite a sequential decline due to a higher-than-expected proportion of flower that did not meet international specifications [12][17] - The company maintained the number one position in overall vapes with a 20.4% market share and moved to the number two position in overall pre-rolls at 7.7% [8][10] - In beverages, market share increased by 80 basis points year-over-year to 5.9%, while in concentrates, the company achieved a 15.5% category share [8][10] Market Data and Key Metrics Changes - The company holds the number one market share position in Canada with 11.3% total share in Q1 and 11.7% over the past 12 months [5][6] - In Quebec, the company moved up to the number three position with 9.9% market share for the quarter, driven by successful vape launches [7] - The company outperformed in most provinces, holding 33.1% market share in New Brunswick and 21.9% in Newfoundland [8] Company Strategy and Development Direction - The company is focused on operational execution, improving margins, and delivering to markets while balancing risk and growth opportunities in international markets [29][30] - The company aims to expand into international markets prudently while maintaining a strong focus on consumer needs and innovation [30][31] - The company is optimistic about long-term growth in the cannabis industry and its ability to compete and lead as the market matures [5] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the impact of the BC General Employees' Union strike and increased competition in vapes and pre-rolls on market share [6][15] - The company remains confident in its ability to deliver against previously issued guidance, expecting revenue to exceed CAD 300 million for the full year [24] - Management expressed optimism about international sales growth in fiscal 2026, despite temporary issues with product specifications [12][13] Other Important Information - The company harvested over 28,000 kilograms of flower in Q1, representing a 43% year-over-year increase, driven by improved yields and ongoing refinements [10] - The company announced a proprietary breakthrough in powdery mildew resistance, allowing for quicker screening of seedlings [11] - Total cash and short-term investments at quarter end were CAD 63 million, including CAD 7.6 million of unrestricted cash [23] Q&A Session Summary Question: Near-term opportunities and prioritization of initiatives - Management emphasized operational execution and cost base improvement as short-term priorities, while focusing on international expansion for long-term growth [29][30] Question: Insight on international volumes and flower issues - Management noted stringent international flower requirements and identified core drivers of recent issues, expecting to resolve them soon [35] - The estimated impact on international revenue was about CAD 3.5 million due to out-of-spec flower [36] Question: Recovery in the Canadian market - Management confirmed recovery in BC distribution levels and acknowledged increased competition in vapes and pre-rolls, with plans for new innovations to regain market share [42][43] Question: EU GMP certification timeline - Management is working closely with regulators to address feedback and is unable to provide a specific timeline for certification [47][48] Question: Route to market in Europe - Management indicated a mixed approach for market entry, utilizing both direct sales and partnerships depending on regulations [51][53] Question: U.S. market investment strategy - Management stated that the U.S. market is currently a minor part of the business, and they are being cautious with investments due to regulatory uncertainties [55][56]

Industry Overview - The U.S. cannabis sector is evolving in early 2026, presenting both risks and opportunities for investors [1] - Regulatory uncertainty has shifted focus towards efficiency, balance sheet repair, and selective growth among operators [1][2] - Potential federal reforms could significantly reshape industry valuations, prompting investors to be more selective [1][2] Investment Focus - Traders are prioritizing companies with established market positions, improving cash flow, and scalable infrastructure [2] - Multi-state operators are expected to benefit from future regulatory changes, including federal tax treatment and banking access [2] Market Volatility - The cannabis market remains volatile, necessitating disciplined risk management [3] - Many stocks are trading below previous highs, creating opportunities for patient investors [3] - Weaker operators may face challenges if capital markets remain tight, emphasizing the importance of company selection [3] February 2026 Outlook - February 2026 is anticipated to be significant for the sector, influenced by earnings updates, regulatory news, and market sentiment [4] - Investors are looking for stocks that combine scale, brand strength, and improved financial discipline [4] Featured Companies AYR Wellness Inc. (AYRWF) - AYR Wellness is a vertically integrated operator with a growing national footprint, primarily in Florida and other states [6][8] - The company focuses on operational control across the supply chain, allowing adjustments based on market demand [9] - Recent restructuring efforts aim to strengthen liquidity and reduce financial strain, with a focus on cost control and cash flow trends [10][11] Cresco Labs Inc. (CRLBF) - Cresco Labs is a well-established multi-state operator with a strong presence in both medical and adult-use markets [12][14] - The company emphasizes brand consistency and consumer trust, with a dual approach of retail and wholesale operations [15] - Financially, Cresco generates high revenue totals, focusing on improving adjusted EBITDA and operating cash flow [16][17] Glass House Brands Inc. (GLASF) - Glass House Brands operates with a strong focus on California, utilizing large greenhouse facilities for cost-efficient production [18][20] - The company emphasizes operational efficiency and quality control through vertical integration [21] - Financial performance has been uneven due to market challenges, but increased production volumes and potential regulatory improvements could support future growth [22][23]

Core Viewpoint - The U.S. cannabis sector is evolving as 2026 begins, with multi-state operators positioned for long-term growth despite ongoing volatility creating both risks and opportunities. Investors are focusing on companies with scale and brand strength, specifically AYR Wellness, Curaleaf Holdings, and Verano Holdings [1]. AYR Wellness Inc. (AYRWF) - AYR Wellness is a vertically integrated cannabis operator with a growing national footprint, operating cultivation, manufacturing, and retail assets across several states. The company serves both medical and adult-use customers and emphasizes premium flower and derivative products [2]. - AYR has faced industry-wide challenges, with revenue growth slowing due to pricing pressure and competition. However, it continues to generate meaningful top-line sales, and gross margins remain stable compared to peers. Operating expenses are elevated, impacting profitability, but liquidity management remains a priority [4]. Curaleaf Holdings Inc. (CURLF) - Curaleaf is one of the largest cannabis companies in the U.S., with a broad footprint across many legalized states and dozens of dispensaries. The company serves both medical and adult-use consumers, offering a wide range of branded products [5][7]. - Financially, Curaleaf demonstrates relative strength with high revenue, although year-over-year growth has slowed. Gross margins remain competitive, and operating cash flow has improved, supporting balance sheet flexibility. Cost controls have helped protect margins, and international operations contribute to incremental growth [9]. Verano Holdings Corp. (VRNOF) - Verano Holdings operates dispensaries across multiple high-value states and has a strong retail focus. The company prioritizes disciplined expansion in markets with strong demand fundamentals and emphasizes premium branding and customer experience [10]. - Despite generating significant revenue, Verano faces profitability challenges due to pricing compression affecting margins. Elevated operating expenses and interest costs have led to persistent net losses, but cash reserves support near-term operations. Management is focused on improving efficiency and reducing long-term expenses [12]. Overall Market Outlook - As January 2026 unfolds, the U.S. cannabis market is in transition, with AYR Wellness, Curaleaf, and Verano each offering unique strengths and sizable retail footprints. Financial discipline is critical, and investors should closely monitor margins, cash flow, and balance sheets as market conditions may improve over time [14].

Core Viewpoint - Cronos Group Inc. is acquiring CanAdelaar B.V. for an up-front cash consideration of US$67.0 million, plus additional cash earnouts based on normalized EBITDA for 2026 and 2027, positioning Cronos as the market leader in the Netherlands' adult-use cannabis market [1][2]. Transaction Overview - The acquisition involves an up-front payment of €57.5 million (US$67.0 million), representing approximately 1.4 times CanAdelaar's last twelve months (LTM) revenue and 2.4 times LTM EBITDA [1][8]. - The transaction is expected to close in early 2026, pending regulatory approvals in the Netherlands [9]. Strategic Rationale - The acquisition is seen as financially compelling and strategically important for establishing a footprint in Europe and leveraging investments in borderless products [2][12]. - CanAdelaar is the largest cannabis company in the Netherlands' adult-use cannabis pilot program, known as the Wietexperiment, which is designed to create a regulated cannabis supply chain [3][4]. Market Context - The Wietexperiment was enacted in 2020 and officially launched in April 2025, allowing for the sale of cannabis in ten municipalities, with the potential for expansion [3][12]. - CanAdelaar has a current cultivation yield of approximately 20,000 kg of dried flower annually and is the only industrial-scale greenhouse cultivator in the Wietexperiment [6][12]. Financial Performance - CanAdelaar's revenue is projected to grow from US$17.7 million in 2024 to US$47.3 million for the twelve months ending September 30, 2025 [6]. - EBITDA is expected to increase from US$8.0 million in 2024 to US$28.2 million for the twelve months ending September 30, 2025 [7]. Competitive Positioning - CanAdelaar holds the leading market share within the Wietexperiment, with active sales to nearly all 72 coffee shops involved in the program [5][12]. - The regulatory framework of the Wietexperiment is designed to promote responsible adult use, potentially serving as a model for other countries [12].

Industry Overview - The U.S. cannabis industry is projected to approach $45 billion by 2025, driven by increasing demand for both medical and recreational use as more states expand access [1] - Marijuana penny stocks are gaining popularity due to their potential for sharp gains and quick movements, especially with recent optimism surrounding possible federal rescheduling [1][2] AYR Wellness Inc. (AYRWF) - AYR Wellness is a multi-state operator with a strong presence in Florida, operating over 70 dispensaries across the U.S. and focusing on both medical and recreational markets [3][5] - The company is recognized for its commitment to customer experience, product consistency, and strong branding, positioning itself as a developing leader among penny-level operators [3][6] - Recent financial performance shows stable revenue, with a focus on cost reduction and operational improvements to support sustainable profitability [5][6] Cansortium Inc. (CNTMF) - Cansortium operates under the Fluent brand, primarily in Florida, with over 30 dispensaries and a focus on high-quality medical products [7][10] - The company emphasizes operational efficiency and has streamlined its operations to improve gross margins and cash flow [10] - Despite facing regulatory costs and market saturation, Cansortium's controlled growth strategy and expanding patient network provide significant upside potential [10] Verano Holdings Corp. (VRNO) - Verano is a major multi-state operator with over 130 dispensaries, known for its premium brands and vertically integrated infrastructure [11][12] - The company has invested heavily in cultivation and manufacturing, ensuring reliable product quality and a diverse product lineup [12][13] - Recent financial performance indicates revenue growth driven by rising consumer adoption, although regulatory costs continue to pressure net profits [15]

Financial Performance - SNDL achieved a record $16.7 million in Free Cash Flow in Q3 2025, driven by working capital improvements in Cannabis Operations and Liquor segments[14, 17] - Net Revenue increased by 3.1% year-over-year to $244 million[14] - Gross Profit increased by 1.9% year-over-year to $64.2 million[14] - Adjusted Operating Income increased by 42.7% year-over-year to $(9.5) million[14] Segment Performance - Liquor Retail net revenue decreased by $(5.2) million or (3.6)% year-over-year to $139.4 million, with gross profit decreasing by $(0.2) million or (0.7)% year-over-year to $36.7 million[36] - Cannabis Retail net revenue increased by $3.9 million or 4.8% year-over-year to $85.0 million, with gross profit increasing by $1.8 million or 8.5% year-over-year to $22.5 million[39, 40] - Cannabis Operations net revenue increased by $12.4 million or 50% year-over-year to $37.4 million, but gross profit decreased by $(0.3) million or (5.6)% year-over-year to $5.0 million[45, 46] Strategic Priorities - Cannabis Retail same store sales grew by 3.6%[51] - Wine & Beyond same store sales grew by 2.9%, supported by private label growth of 13.3%[51] - Cannabis Operations experienced 50% year-over-year revenue growth, driven by edibles and international sales[52]

High Tide Conference Call Summary Company Overview - **Company Name**: High Tide (NasdaqCM: HITI) - **Ticker**: HITI on NASDAQ since 2021 and TSX Venture Exchange since 2018 - **Main Operating Company**: Canna Cabana, the largest retail cannabis brand in Canada with over 207 stores [2][3] Financial Performance - **Trailing Revenue**: Approximately CAD 683 million, including recent acquisitions [2] - **Adjusted EBITDA**: CAD 58 million, with a pro forma trailing adjusted EBITDA multiple of 8.8 times [3] - **Same-Store Sales Growth**: Up 137% since October 2021, compared to a 2% decline for peers [4][14] - **Market Share**: 12% in the five provinces of operation, with a target to reach 15% [4][15] - **Revenue per Square Foot**: CAD 1,735, outperforming many blue-chip retailers [5][16] - **Free Cash Flow**: Generated CAD 4 million in July 2023, five months ahead of schedule [25][26] Recent Developments - **Acquisition**: Acquired 51% of Ramexian Pharma, a leading medical cannabis importer in Germany, for €26.4 million [19] - **Market Expansion**: Entering the German market, which has seen a significant increase in patient counts from 250,000 to 900,000 [20][21] - **Growth in German Cannabis Imports**: Annualized imports increased from CAD 30-40 million to CAD 300 million post-reclassification of medical cannabis [23] Strategic Insights - **Retail Strategy**: Focus on smaller, efficient store sizes (1,200 to 1,500 square feet) rather than larger stores [9][18] - **Loyalty Program**: 2.15 million loyalty members, with 115,000 ELITE members paying CAD 35 annually for additional discounts [4][12] - **Consumer Preferences**: Pre-rolls and dried flower account for about two-thirds of sales, with vapes at 22% [7][8] Market Context - **Canadian Cannabis Market**: Legalized in October 2018, now a CAD 5.5 billion market, with Canna Cabana's operations in a CAD 4.5 billion retail market [6] - **Competitive Landscape**: Canna Cabana's average store revenue significantly exceeds that of peers, with Alberta stores averaging CAD 2.3 million and Ontario stores over CAD 3.1 million [14][15] Future Outlook - **Store Growth**: Targeting to exceed 300 stores, with plans to open 20-30 new stores annually [27] - **Vertical Integration**: Exploring opportunities in cannabis accessories and white-label products, though full vertical integration is limited by regulations [34][36] - **International Expansion**: Monitoring other European markets (UK, Poland, Czech Republic, Switzerland) for potential entry [32] Key Takeaways - High Tide is positioned as a leading innovative retailer in the cannabis space, with strong financial metrics and growth potential in both Canada and Germany [41] - The company is leveraging its retail relationships to capitalize on the growing medical cannabis market in Germany, aiming for significant market share [42]

Industry Overview - The U.S. cannabis industry is rapidly expanding, with legal sales reaching nearly $30 billion in 2024 and projected to surpass $45 billion by 2028, driven by increased state legalization and changing consumer demand [1][3] - Federal rescheduling discussions are ongoing, with lawmakers considering moving cannabis to Schedule III, which could enhance banking access and reduce tax burdens [1][3] Key Companies - Green Thumb Industries Inc. (GTBIF), Curaleaf Holdings Inc. (CURLF), and Verano Holdings Corp. (VRNOF) are highlighted as top stocks to watch, each operating numerous dispensaries and possessing significant cultivation capacity [4][6][27] Green Thumb Industries Inc. (GTBIF) - Green Thumb operates over 90 dispensaries, primarily in Illinois, Pennsylvania, and Ohio, and is recognized as a vertically integrated operator with control over cultivation, processing, and retail [5][7] - The company reported quarterly revenue exceeding $275 million, maintaining profitability and showing resilience despite challenges in competitive markets [9][11] - Green Thumb's financials indicate improved margins due to higher retail sales and efficient operations, with stable debt levels enhancing financial flexibility [10][11] Curaleaf Holdings Inc. (CURLF) - Curaleaf operates over 140 dispensaries across more than 15 states, with a strong presence in Florida, New York, New Jersey, and Arizona [12][15] - The company posted quarterly revenue above $330 million, confirming its status as the largest revenue generator among U.S. cannabis companies, while also reducing operating losses [16][18] - Curaleaf's aggressive acquisition strategy and focus on high-demand markets position it as a competitive player in the industry [15][19] Verano Holdings Corp. (VRNOF) - Verano operates more than 140 dispensaries, primarily in Florida, New Jersey, and Illinois, and emphasizes customer experience and premium store design [19][21] - The company reported quarterly revenue of around $235 million, with positive adjusted EBITDA and improved operating income due to reduced expenses [24][25] - Verano's ongoing expansion and financial discipline, along with manageable debt levels, make it a significant competitor in the U.S. cannabis market [26][27]

Financial Performance - Record gross revenue of $110.2 million, a 73% increase year-over-year and a 7.2% sequential increase[86] - Record net revenue of $70.8 million, a 72% increase year-over-year and a 7.9% sequential increase[86] - Adjusted EBITDA of $5.7 million, a 64% increase year-over-year and a 16% sequential increase[86] - International revenue reached $7.4 million, a 208% increase year-over-year and a 21% sequential increase[86] - Free cash flow was $5.0 million, compared to ($4.8) million in the prior year period[86] Strategic Initiatives - Completed the acquisition of Motif Labs Ltd, expecting approximately $15 million in run-rate cost synergies[44] - Completed the acquisition of Collective Project Limited, fast-tracking entry into the cannabinoid beverages category and the U S market[47] - Strategic investments from BAT totaled over $345 million to fund research & development and international M&A[48] - Invested $21 million into German cannabis leader Sanity Group to establish a foothold in the rapidly growing German market and expand export volume to Europe[61] - 27% of flower harvest at Moncton facility was seed-based in Q3 Fiscal 2025[65] Market Position - Organigram is the 1 LP in market share in Canada[17] - 1 in vapes, 1 in pre-rolls, 1 in milled flower, 1 in hash, 3 in edibles, 3 in dried flower in Canada[86]